James H Lan1,2,3, Matthew Kadatz1,3, Doris T Chang4, Jagbir Gill5,4,6,7, Howard M Gebel8, John S Gill5,4,9. 1. Vancouver Coastal Health Research Institute, Vancouver, Canada. 2. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. 3. Division of Nephrology, Kidney Transplant Program, University of British Columbia, Vancouver, Canada. 4. Providence Health Research Institute, Vancouver, Canada. 5. Division of Nephrology, Kidney Transplant Program, University of British Columbia, Vancouver, Canada jgill@providencehealth.bc.ca. 6. Centre for Health Evaluation and Outcomes Sciences, Vancouver, Canada. 7. School of Population and Public Health, University of British Columbia, Vancouver, Canada. 8. Department of Pathology, Emory University, Atlanta, Georgia. 9. Division of Nephrology, Tufts-New England Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: Panel reactive antibody informs the likelihood of finding an HLA-compatible donor for transplant candidates, but has historically been associated with acute rejection and allograft survival because testing methods could not exclude the presence of concomitant donor-specific antibodies. Despite new methods to exclude donor-specific antibodies, panel reactive antibody continues to be used to determine the choice of induction and maintenance immunosuppression. The study objective was to determine the clinical relevance of panel reactive antibody in the absence of donor-specific antibodies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Retrospective observational study of kidney allograft survival among 4058 zero HLA-A-, B-, DR-, and DQB1-mismatched transplant recipients without antibodies to donor kidney antigens encoded by these HLA gene loci. RESULTS: Among 4058 first and repeat transplant recipients, patients with calculated panel reactive antibody (cPRA) 1%-97% were not at higher risk of transplant failure, compared with patients with cPRA of 0% (death censored graft loss: hazard ratio, 1.07; 95% confidence interval, 0.82 to 1.41). Patients with cPRA ≥98% had a higher risk of graft loss from any cause including death (hazard ratio, 1.39; 95% confidence interval, 1.08 to 1.79) and death censored allograft failure (hazard ratio, 1.78; 95% confidence interval, 1.27 to 2.49). In stratified analyses, the higher risk of graft loss among patients with cPRA ≥98% was only observed among repeat, but not first, transplant recipients. In subgroup analysis, there was no association between cPRA and graft loss among living related transplant recipients. CONCLUSIONS: Calculated panel reactive antibody is poorly associated with post-transplant immune reactivity to the allograft in the absence of donor-specific antibody. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_01_25_CJN13640820_final.mp3.
BACKGROUND AND OBJECTIVES: Panel reactive antibody informs the likelihood of finding an HLA-compatible donor for transplant candidates, but has historically been associated with acute rejection and allograft survival because testing methods could not exclude the presence of concomitant donor-specific antibodies. Despite new methods to exclude donor-specific antibodies, panel reactive antibody continues to be used to determine the choice of induction and maintenance immunosuppression. The study objective was to determine the clinical relevance of panel reactive antibody in the absence of donor-specific antibodies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Retrospective observational study of kidney allograft survival among 4058 zero HLA-A-, B-, DR-, and DQB1-mismatched transplant recipients without antibodies to donor kidney antigens encoded by these HLA gene loci. RESULTS: Among 4058 first and repeat transplant recipients, patients with calculated panel reactive antibody (cPRA) 1%-97% were not at higher risk of transplant failure, compared with patients with cPRA of 0% (death censored graft loss: hazard ratio, 1.07; 95% confidence interval, 0.82 to 1.41). Patients with cPRA ≥98% had a higher risk of graft loss from any cause including death (hazard ratio, 1.39; 95% confidence interval, 1.08 to 1.79) and death censored allograft failure (hazard ratio, 1.78; 95% confidence interval, 1.27 to 2.49). In stratified analyses, the higher risk of graft loss among patients with cPRA ≥98% was only observed among repeat, but not first, transplant recipients. In subgroup analysis, there was no association between cPRA and graft loss among living related transplant recipients. CONCLUSIONS: Calculated panel reactive antibody is poorly associated with post-transplant immune reactivity to the allograft in the absence of donor-specific antibody. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_01_25_CJN13640820_final.mp3.
Authors: Henrik Ekberg; Helio Tedesco-Silva; Alper Demirbas; Stefan Vítko; Björn Nashan; Alp Gürkan; Raimund Margreiter; Christian Hugo; Josep M Grinyó; Ulrich Frei; Yves Vanrenterghem; Pierre Daloze; Philip F Halloran Journal: N Engl J Med Date: 2007-12-20 Impact factor: 91.245
Authors: Annette M Jackson; Tara K Sigdel; Marianne Delville; Szu-Chuan Hsieh; Hong Dai; Serena Bagnasco; Robert A Montgomery; Minnie M Sarwal Journal: J Am Soc Nephrol Date: 2014-11-07 Impact factor: 10.121
Authors: Christian Noël; Daniel Abramowicz; Dominique Durand; Georges Mourad; Philippe Lang; Michèle Kessler; Bernard Charpentier; Guy Touchard; François Berthoux; Pierre Merville; Nacera Ouali; Jean-Paul Squifflet; François Bayle; Karl Martin Wissing; Marc Hazzan Journal: J Am Soc Nephrol Date: 2009-05-21 Impact factor: 10.121
Authors: Liesbeth Daniëls; Frans H J Claas; Cynthia S M Kramer; Aleksandar Senev; Marleen Vanden Driessche; Marie-Paule Emonds; Steven Van Laecke; Rachel Hellemans; Daniel Abramowicz; Maarten Naesens Journal: Transpl Immunol Date: 2020-03-16 Impact factor: 1.708
Authors: Rhys D R Evans; James H Lan; Matthew Kadatz; Sandeep Brar; Doris T Chang; Lachlan McMichael; Jagbir Gill; John S Gill Journal: Clin J Am Soc Nephrol Date: 2022-02 Impact factor: 10.614